A Randomized, Controlled Trial Comparing Tearcare^® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA)

References

• Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318–326. doi:10.1016/S0002-9394(03)00218-6
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the physicians’ health studies. Arch Ophthalmol. 2009;127:763–768. doi:10.1001/archophthalmol.2009.103
   PubMed Web of Science ®Google Scholar
• Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52:1922–1929. doi:10.1167/iovs.10-6997a
   PubMed Web of Science ®Google Scholar
• Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472–478. doi:10.1097/ICO.0b013e318225415a
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631–639. doi:10.1016/S0161-6420(99)00176-1
   PubMed Web of Science ®Google Scholar
• Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized Phase III OPUS-2 study. Ophthalmology. 2015;122:2423–2431. doi:10.1016/j.ophtha.2015.08.001
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–483. doi:10.1016/j.ophtha.2013.09.015
   PubMed Web of Science ®Google Scholar
• Wirta D, Vollmer P, Paauw J, et al. Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology. 2022;129(4):379–387. doi:10.1016/j.ophtha.2021.11.004
   PubMed Web of Science ®Google Scholar
• Wirta D, Torkildsen GL, Boehmer B, et al. ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease. Cornea. 2022;41(10):1207–1216. doi:10.1097/ICO.0000000000002941
   PubMed Web of Science ®Google Scholar
• Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):2050–2064. doi:10.1167/iovs.10-6997g
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. TearCare system indications for use. Available from: https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K213045;. Accessed July 26, 2023.
   Google Scholar
• Badawi D. TearCare® system extension study: evaluation of the safety, effectiveness, and durability through 12 months of a second TearCare® treatment on subjects with dry eye disease. Clin Ophthalmol. 2019;13:189–198. doi:10.2147/OPTH.S191588
   PubMed Web of Science ®Google Scholar
• Gupta PK, Holland EJ, Hovanesian J, et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea. 2022;41:417–426. doi:10.1097/ICO.0000000000002837
   PubMed Web of Science ®Google Scholar
• Blackie CA, Solomon JD, Greiner JV, Holmes M, Korb DR. Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci. 2008;85(8):675–683. doi:10.1097/OPX.0b013e318181adef
   PubMed Web of Science ®Google Scholar
• Dhamdhere K, Badawi D. A blink-assisted, cornea-sparing wearable eyelid device for the effective penetration of therapeutic thermal energy into the meibomian glands for the treatment of dry eye disease. J Clin Exp Ophthalmol. 2021;S12:003.
   Google Scholar
• Holland EJ, Loh J, Bloomenstein M, Thompson V, Wirta D, Dhamdhere K. A comparison of TearCare and lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clin Ophthalmol. 2022;16:2861–2871. doi:10.2147/OPTH.S368319
   PubMed Web of Science ®Google Scholar
• Foulks GN. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin. 2006;46:105–122. doi:10.1097/01.iio.0000212135.77675.6a
   PubMedGoogle Scholar
• US Food and Drug Administration. Restasis prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf;. Accessed November 16, 2021.
   Google Scholar
• Schwartz LM, Woloshin S. A clear-eyed view of restasis and chronic dry eye disease. JAMA Internal Med. 2018;178:181–182. doi:10.1001/jamainternmed.2017.7904
   PubMed Web of Science ®Google Scholar
• Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010;18(5):352–361. doi:10.3109/09273948.2010.498657
   PubMed Web of Science ®Google Scholar
• Sight Sciences Inc. TearCare System Instructions for Use. Sight Sciences Inc; 2022.
   Google Scholar
• Korb DR, Blackie CA. Meibomian gland diagnostic expressibility: correlation with dry eye symptoms and gland location. Cornea. 2008;27(10):1142–1147. doi:10.1097/ICO.0b013e3181814cff
   PubMed Web of Science ®Google Scholar
• Lane SS, DuBiner HB, Epstein RJ, et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. 2012;31(4):396–404. doi:10.1097/ICO.0b013e318239aaea
   PubMed Web of Science ®Google Scholar
• Badawi D. A novel system, TearCare®, for the treatment of the signs and symptoms of dry eye disease. Clin Ophthalmol. 2018;12:683–694. doi:10.2147/OPTH.S160403
   PubMed Web of Science ®Google Scholar
• Karpecki P, Wirta D, Osmanovic S, Dhamdhere K. A prospective, post-market, multicenter trial (CHEETAH) suggested TearCare system as a safe and effective blink-assisted eyelid device for the treatment of dry eye disease. Clin Ophthalmol. 2020;14:4551–4559. doi:10.2147/OPTH.S285953
   PubMed Web of Science ®Google Scholar
• Chester T. A single-center retrospective trial of a blink-assisted eyelid device in treating the signs and symptoms of dry eye. Optom Vis Sci. 2021;98:605–612. doi:10.1097/OPX.0000000000001711
   PubMed Web of Science ®Google Scholar
• Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007;26:805–809. doi:10.1097/ICO.0b013e318074e460
   PubMed Web of Science ®Google Scholar
• van Onzenoort HA, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58:573–578. doi:10.1161/HYPERTENSIONAHA.111.171074
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497. doi:10.1056/NEJMra050100
   PubMed Web of Science ®Google Scholar
• Kawashima M, Sano K, Takechi S, Tsubota K. Impact of lifestyle intervention on dry eye disease in office workers: a randomized controlled trial. J Occup Health. 2018;60:281–288. doi:10.1539/joh.2017-0191-OA
   PubMed Web of Science ®Google Scholar
• Mertzanis P, Venkataraman K, Begley C, Chalmers R, Abetz L. The impact of dry eye on daily life: results from a qualitative study. Invest Ophthalmol Vis Sci. 2002;43:74.
   Web of Science ®Google Scholar
• Nichols KK, Bacharach J, Holland E, et al. Impact of dry eye disease on work productivity, and patients’ satisfaction with over-The-counter dry eye treatments. Invest Ophthalmol Vis Sci. 2016;57:2975–2982. doi:10.1167/iovs.16-19419
   PubMed Web of Science ®Google Scholar
• Uchino M, Yokoi N, Shimazaki J, et al. Adherence to eye drops usage in dry eye patients and reasons for non-compliance: a web-based survey. J Clin Med. 2022;11(2):367. doi:10.3390/jcm11020367
   PubMed Web of Science ®Google Scholar
• Chester T, Ferguson T, Chester E. Localized heat treatment for meibomian gland dysfunction: a single-center retrospective analysis of efficacy over time. Optom Vis Sci. 2023;100(9):625–630. doi:10.1097/OPX.0000000000002053
   PubMed Web of Science ®Google Scholar